Tentative Approval — This application has been tentatively approved by the FDA but is not yet listed in the Orange Book. It is blocked from final approval by unexpired patents or exclusivities on the reference listed drug.
LASMIDITAN | A219350 | QILU PHARMACEUTICAL CO., LTD.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ELI LILLY & COMPANY et al v. QILU PHARMACEUTICAL CO., LTD. et al 1 patentANDA 219350lasmiditan | D.N.J. | 2026-03-19 | Terminated 2026-04-02 | — |
ELI LILLY & COMPANY et al v. QILU PHARMACEUTICAL CO., LTD. et al 1 patentANDA 219350lasmiditan | D.N.J. | 2025-06-30 | Terminated 2025-07-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.